Limitations in the Assessment of Prosthesis-Patient Mismatch.


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 5 1 2019
medline: 16 12 2020
entrez: 5 1 2019
Statut: ppublish

Résumé

Prosthesis-patient mismatch (PPM) after aortic valve replacement (AVR) may affect survival but data are conflicting. It is assessed by relating effective orifice area (EOA) to body surface area (EOAi). EOA is patient-specific as the result of flow-velocity times area at the individual patient's outflow tract levels (LVOT We analyzed 76 studies addressing hemodynamic outcome and/or mortality after bioprosthetic AVR. In 48 studies, projected or measured EOA for calculation of EOAi and PPM assessment was used (of which 25 demonstrated an effect on survival). We identified 28 additional studies providing measured EOA values and the corresponding Bernoulli's pressure gradients after AVR. Despite EOA being a patient-specific parameter, 77% of studies assessing a PPM impact on survival used projected EOAs. The 28 studies are providing measured EOA values and the corresponding Bernoulli's pressure gradients in patients after AVR showed a highly significant, linear relationship between EOA and Bernoulli's gradient. Considering this relationship, it is surprising that relating EOA to body surface area (BSA) (EOAi) is standard but relating pressure gradients to BSA is not. We conclude that the majority of studies assessing PPM have used false assumptions because EOA is a patient-specific parameter and cannot be transferred to other patients. In addition, the use of EOAi to assess PPM may not be appropriate and could explain the inconsistent relation between PPM and survival in previous studies.

Sections du résumé

BACKGROUND
Prosthesis-patient mismatch (PPM) after aortic valve replacement (AVR) may affect survival but data are conflicting. It is assessed by relating effective orifice area (EOA) to body surface area (EOAi). EOA is patient-specific as the result of flow-velocity times area at the individual patient's outflow tract levels (LVOT
METHODS
We analyzed 76 studies addressing hemodynamic outcome and/or mortality after bioprosthetic AVR.
RESULTS
In 48 studies, projected or measured EOA for calculation of EOAi and PPM assessment was used (of which 25 demonstrated an effect on survival). We identified 28 additional studies providing measured EOA values and the corresponding Bernoulli's pressure gradients after AVR. Despite EOA being a patient-specific parameter, 77% of studies assessing a PPM impact on survival used projected EOAs. The 28 studies are providing measured EOA values and the corresponding Bernoulli's pressure gradients in patients after AVR showed a highly significant, linear relationship between EOA and Bernoulli's gradient. Considering this relationship, it is surprising that relating EOA to body surface area (BSA) (EOAi) is standard but relating pressure gradients to BSA is not.
CONCLUSION
We conclude that the majority of studies assessing PPM have used false assumptions because EOA is a patient-specific parameter and cannot be transferred to other patients. In addition, the use of EOAi to assess PPM may not be appropriate and could explain the inconsistent relation between PPM and survival in previous studies.

Identifiants

pubmed: 30609446
doi: 10.1055/s-0038-1676814
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

550-556

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Author T.D. received occasional honoraria from St. Jude Medical, Inc. for lectures on aortic valve topics. All other authors have nothing to disclose.

Auteurs

Paulo A Amorim (PA)

Department of Cardiothoracic Surgery, Friedrich Schiller University Jena, Jena, Germany.

Mahmoud Diab (M)

Department of Cardiothoracic Surgery, Friedrich Schiller University Jena, Jena, Germany.

Mario Walther (M)

Department of Basic Sciences, University of Applied Sciences Jena, Jena, Germany.

Gloria Färber (G)

Department of Cardiothoracic Surgery, Friedrich Schiller University Jena, Jena, Germany.

Andreas Hagendorff (A)

Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Robert O Bonow (RO)

Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine Chicago, Chicago, Germany.

Torsten Doenst (T)

Department of Cardiothoracic Surgery, Friedrich Schiller University Jena, Jena, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH